Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + RT + LHRHa in High-Risk Hormone-Sensitive Prostate Cancer
NCT04557059Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Aug 2029
- Modality
- Orthosteric Ligands
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Primary endpoint: Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival up to 9 years. Started Nov 2020; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04557059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557059.